This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Contact Us
product logo 
For other use than food/dietary supplements

A Highly Documented Probiotic for Serious Gut Conditions

IBacilluS+ is a probiotic formula combining two safe and strong bacteria strains E. faecium Rosell®-26 and B. subtilis Rosell®-179. The product is a success story in Asia where it has been sold since 1980s.

The beneficial health effects of IBacilluS+ on special care and severe gut disorders have been studied in various meta-analyses and clinical trials, involving more than 6,000 participants:

  • 1 meta-analysis on Irritable Bowel Syndrome (IBS): 15 clinical trials in adults [Chen, 2012]
  • 2 meta-analyses on Ulcerative Colitis (UC), in combination with conventional treatment: 24 clinical trials [Hu, 2013], 53 clinical trials [Sohail, 2018]

2 recent innovative studies on reflux esophagitis and small intestine bacterial overgrowth

  • Reflux Esophagitis (RE) and Small Intestine Bacterial Overgrowth (SIBO) following esomeprazole intake [Sun, 2019]
  • SIBO and modulation of microflora in participants with functional bowel disorders [Shi, 2020]

These new clinical findings are also supported by approved health claims in Canada:

  • Helps reduce the reappearance of reflux esophagitis symptoms following proton pump inhibitor treatment.
  • Helps extend time between reappearance of reflux esophagitis symptoms following proton pump inhibitor treatment.
  • Helps reduce the risk of Small Intestine Bacterial Overgrowth after proton pump inhibitor treatment.

Additional studies on gut health and promising effects on metabolic health

  • 1 meta-analysis on Antibiotic-Associated Diarrhea (AAD): 16 clinical trials in infants, children and adults [Lui, 2012]
  • 1 recent clinical trial on Antibiotic-Associated Diarrhea (AAD) in infants and children [Rui, 2020]
  • 1 clinical trial on Helicobacter pylori infection [Park, 2007]
  • 1 clinical trial on non-alcoholic fatty liver disease in adults [Yang, 2012]

© 2024 Lallemand Inc. All right reserved.
The information contained herein is business-to-business information and is not intended for the final consumer. It is based on our research and development work and is, to the best of our knowledge, reliable. Lallemand Health Solutions does not assume any liability resulting from the use of its products, as conditions of use are beyond our control. The business-to-business information provided should not be used as a substitute for any form of advice. In all instances, producers and marketers should check local regulatory requirements before use as different claims may be made depending on the regulations applicable in each country.